Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 939-137-4 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
There are no specific experimental data available concerning toxicokinetics, metabolism and distribution for CHEP. Based on the physicochemical properties of the substance and available ecotoxicological and toxicological information it is concluded that the substance is systemically bioavailable after oral, dermal and inhalative administration. The substance has a low potential for bioaccumulation.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
Additional information
Assessment of the Toxicokinetic Behaviour
Since no toxicokinetic studies are available for the reaction mass of 2-piperazine-1-ylethanol and piperazine-1,4-diethanol and piperazine and water (CHEP), the following assessment is based on the available physicochemical properties and results from other toxicological studies. Furthermore some ADME studies are available from piperazine which is one constituent of the test substance. These can be taken into account because the physicochemical properties are similar for the three major constituents.
CHEP is a liquid, viscous, organic, colourless substance with a small molecular weight for each of the three main components (CAS 103-76-4: 130.1882 g/mol, CAS 122-93-3: 174.24 g/mol, CAS 110-85-0: 86.1356 g/mol) indicative for a favourable absorbance of the test item.
Absorption
The partition coefficient of the test substance (Log Pow) is -1.55 at 23°C at pH 11.3. Based on this rather low partition coefficient the test substance is unlikely to bioaccumulate with the repeated intermittent exposure patterns normally encountered. However, this low log Pow value, the high water solubility and the small molecular weight indicate that the substance might be favourable for passive diffusion. In line with this, in an acute oral toxicity study with CAS 103-76-4, 5/5 females and 3/5 males died after administration of 5305 mg/kg bw and 1/5 males and 3/5 females died after administration of 4244 mg/kg bw, respectively. After administration of 3396 mg/kg bw 1/5 male and 2/5 females and at 1698 mg/kg bw 1/10 animals died (-> LD50 = 4244 mg/kg bw). Furthermore, animals receiving high and intermediate doses showed clinical signs and symptoms, including high stepping gait, motor excitation, intermittent respiration, abdominal position and paresis (hindlimb), immediately after application; piloerection, nose and eyes with reddish crusts, intermittent respiration, apathy and squatting posture until including day 3. These observations are in line with the low log Pow value, showing that the substance is systemically bioavailable when administered orally. It is therefore assumed that the test substance or its possible metabolites become systemically available after absorption along the gastro intestinal tract. These results are in line with the ADME study (Morrison, 1997) done in pig with piperazine (CAS 110-85-0) where the peak plasma level was found after 1 hour after administration.
Furthermore, bioavailability via the dermal route is also assumed but to a lower extend. The LD50 was estimated to be 8300 mg/kg bw in an acute dermal toxicity study with rabbits (CAS 110-85-0, BASF AG, 1977). The animals showed clinical signs such as cyanosis, diarrhea, salivation, mild convulsions, bleeding from mouth and nose, ataxia, loss of righting, abnormal stance, catatonia, ptosis, and decreased activity. Furthermore, the substance is corrosive (BASF AG, 2012) and sensitising after skin contact (EU Risk assessment for piperazine, 2005), further supporting the notion that there is a bioavailability of the substance via the dermal route.
It is shown that piperazine (CAS 110-85-0) induces occupational asthma due to exposure of piperazine (Hagmar, 1983). Therefore, as a worst case assumption, bioavailability via the inhalative route for CHEP is also assumed.
Distribution
For piperazine (CAS 110-85-0, Morrison 1997) the highest radioactivity was found in kidneys and liver after oral administration to pig. Elimination of the activity in the kidney was rapid, with only 3% remaining of the 12h value post dosing. The elimination from the liver, skeleton, muscle, fat and skin was considerably slower with 10, 11, 24, 25% respectively remaining after 7 days in comparison with the 12 h levels.
Since neurotoxic effects were observed after oral application of piperazine to humans(EU Risk assessment, 2005) piperazine is assumed to enter the blood brain barrier.
Metabolism
Piperazine (CAS 110-85-0) was metabolized rapidly to naturally occurring materials in pig after oral administration, largely to polysaccharides and to lower extent amino acids (Hazelton, 1975). For the other two constituents of CHEP no data are available. Using the OECD toolbox vs.3.0, the liver metabolism simulator provided 19 potential simulated metabolites for CAS 103-76-4 and 25 metabolites for CAS 122-96-3, as well as 4 simulated skin metabolites each. A study assessing genotoxicity of the test substance (Ames-Test; BASF 2012) was negative, i.e. there is no indication of a reactivity of the test substance or its metabolites with macromolecules under the chosen test conditions.
Excretion
In the ADME study with piperazine (Morrison, 1997) it was found that piperazine was eliminated to 57% via the urine mainly in the first 24 hours after oral administration. 16% was excreted in faeces. About one fourth of the totally administered amount can be considered as still retained in the body.
For the other two constituents of CHEP no data are available concerning excretion. Based on the molecular weights of these to constituents and their respective water solubilities, it is conjectured that the test substance would probably primarily undergo a renal elimination as seen for piperazine.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.